Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts. more
Time Frame | IVVD | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6.13% | -2.27% | -0.57% |
1-Month Return | -38.54% | -3.96% | 1.21% |
3-Month Return | -52.43% | -9.7% | 7.57% |
6-Month Return | -67.82% | -3.37% | 11.45% |
1-Year Return | -67.25% | 3.71% | 28.48% |
3-Year Return | -98.4% | 3.8% | 29.52% |
5-Year Return | -97.38% | 39.78% | 90.66% |
Dec '20 | Dec '21 | Dec '22 | Dec '23 | |||
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Cost of Revenue | - | 1.00K | 462.00K | 2.03M | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":0.05,"profit":true},{"date":"2022-12-31","value":22.78,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Gross Profit | - | (1.00K) | (462.00K) | (2.03M) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-100000,"profit":false},{"date":"2022-12-31","value":-46200000,"profit":false},{"date":"2023-12-31","value":-202800000,"profit":false}] | |
Gross Margin | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Operating Expenses | 65.33M | 219.41M | 226.26M | 205.75M | [{"date":"2020-12-31","value":28.87,"profit":true},{"date":"2021-12-31","value":96.97,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":90.94,"profit":true}] | |
Operating Income | (65.33M) | (226.91M) | (248.03M) | (207.78M) | [{"date":"2020-12-31","value":-6532700000,"profit":false},{"date":"2021-12-31","value":-22690800000,"profit":false},{"date":"2022-12-31","value":-24803100000,"profit":false},{"date":"2023-12-31","value":-20778300000,"profit":false}] | |
Total Non-Operating Income/Expense | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Pre-Tax Income | (65.32M) | (226.79M) | (241.32M) | (198.64M) | [{"date":"2020-12-31","value":-6531900000,"profit":false},{"date":"2021-12-31","value":-22679000000,"profit":false},{"date":"2022-12-31","value":-24131700000,"profit":false},{"date":"2023-12-31","value":-19864300000,"profit":false}] | |
Income Taxes | (43.20K) | 7.50M | (6.71M) | - | [{"date":"2020-12-31","value":-0.58,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-89.53,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] | |
Income After Taxes | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Income From Continuous Operations | - | (226.79M) | (241.32M) | (169.56M) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-22679000000,"profit":false},{"date":"2022-12-31","value":-24131700000,"profit":false},{"date":"2023-12-31","value":-16956300000,"profit":false}] | |
Income From Discontinued Operations | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Net Income | (65.32M) | (234.29M) | (234.60M) | (198.64M) | [{"date":"2020-12-31","value":-6531900000,"profit":false},{"date":"2021-12-31","value":-23428900000,"profit":false},{"date":"2022-12-31","value":-23460300000,"profit":false},{"date":"2023-12-31","value":-19864300000,"profit":false}] | |
EPS (Diluted) | - | (1.93) | (2.07) | (1.81) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-193,"profit":false},{"date":"2022-12-31","value":-207,"profit":false},{"date":"2023-12-31","value":-181,"profit":false}] | |
These ratios help you determine the liquidity of the company. Higher is better.
IVVD | |
---|---|
Cash Ratio | 1.36 |
Current Ratio | 1.92 |
Quick Ratio | 1.58 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
IVVD | |
---|---|
ROA (LTM) | -53.56% |
ROE (LTM) | -96.56% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
IVVD | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.49 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.51 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
IVVD | |
---|---|
Trailing PE | NM |
Forward PE | 3.87 |
P/S (TTM) | 30.86 |
P/B | 0.83 |
Price/FCF | NM |
EV/R | 3.04 |
EV/Ebitda | 0.78 |
Invivyd Inc. (IVVD) share price today is $0.547
Yes, Indians can buy shares of Invivyd Inc. (IVVD) on Vested. To buy Invivyd Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IVVD stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Invivyd Inc. (IVVD) via the Vested app. You can start investing in Invivyd Inc. (IVVD) with a minimum investment of $1.
You can invest in shares of Invivyd Inc. (IVVD) via Vested in three simple steps:
The 52-week high price of Invivyd Inc. (IVVD) is $5.2. The 52-week low price of Invivyd Inc. (IVVD) is $0.54.
The price-to-earnings (P/E) ratio of Invivyd Inc. (IVVD) is
The price-to-book (P/B) ratio of Invivyd Inc. (IVVD) is 0.83
The dividend yield of Invivyd Inc. (IVVD) is 0.00%
The market capitalization of Invivyd Inc. (IVVD) is $69.86M
The stock symbol (or ticker) of Invivyd Inc. is IVVD